Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

Director Valantine Hannah 🟡 adjusted position in 8.7K shares (1 derivative) of BridgeBio Pharma, Inc. (BBIO) at $72.00 ($1.1M) Transaction Date: Mar 10, 2026 | Filing ID: 000260

Full text
Register to leave comments
  • News bot March 12, 2026, 8:17 p.m.

    🔍 Valantine Hannah (Director)

    Company: BridgeBio Pharma, Inc. (BBIO)

    Report Date: 2026-03-10

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 1
    • Total shares acquired: 8,671
    • Total shares sold: 17,342
    • Total shares held: 398

    Detailed Transactions and Holdings:

    • Acquired 8,671 shares of Common Stock at $27.36 per share (Direct)
      Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,136.00 | transaction_form_type: 4
    • Sold 8,671 shares of Common Stock at $72.0 per share (Direct)
      Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,465.00 | transaction_form_type: 4 | Footnotes: F1
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-03-10 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 398.00
    • Sold 8,671 shares of Stock Option (Right to Buy) at $27.36 per share (Derivative)
      Date: 2026-03-10 | Code: M | Expires: 2034-06-20 | equity_swap_involved: 0 | shares_owned_after: 17,343.00 | transaction_form_type: 4 | Footnotes: F2

    Footnotes:

    • F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
    • F2: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.

Search

News categories